Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<IPO>TransThera Sciences Clears HK Listing Hearing; Last Yr's Loss RMB275M
Recommend 13 Positive 15 Negative 8 |
||||
|
||||
|
TransThera Sciences has passed the listing hearing with HKEX (00388.HK) and is set to go public. The company's core business model centers on the independent development, research, and commercialization of small molecule drugs to address significant medical needs in oncology, inflammation, and cardiovascular metabolic diseases. According to available data, TransThera Sciences recorded revenue of RMB1.181 million in 2023, with no revenue reported for 2024. Its R&D expenses were RMB345 million and RMB244 million, respectively, and it posted losses of RMB343 million and RMB275 million during the respective periods. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
